Search results for " vaccine"

showing 10 items of 680 documents

Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral…

2020

Objectives: The aim of this multicenter study was to investigate the prognostic role of type 2 diabetes mellitus (T2DM) comorbidity in a large multi-institutional cohort of patients with primary T1HG/G3 non–muscle-invasive bladder cancer (NMIBC) treated with transurethral resection of the bladder (TURB). Materials and methods: A total of 1,172 patients with primary T1 HG/G3 who had NMIBC on re-TURB and who received adjuvant intravesical bacillus Calmette-Guérin therapy with maintenance were included. Endpoints were recurrence-free survival and progression-free survival. Results: A total of 231 (19.7%) of patients had T2DM prior to TURB. Five-year recurrence-free survival estimates were 12.5…

Malemedicine.medical_specialtyDiabetes mellituUrologymedicine.medical_treatment030232 urology & nephrologyUrologyCystectomyResection03 medical and health sciences0302 clinical medicineDiabetes mellitusHigh gradeAdjuvants ImmunologicUrethraRecurrenceDiabetes mellitusmedicineHumansIn patientNeoplasm InvasivenessAgedNeoplasm StagingRetrospective StudiesBladder cancerProgressionbusiness.industryHigh riskBladder cancerType 2 Diabetes MellitusMiddle Agedmedicine.diseasePrognosisComorbidityProgression-Free Survival3. Good healthBladder cancer; Diabetes mellitus; High grade; High risk; Progression; RecurrenceSettore MED/24OncologyDiabetes Mellitus Type 2Urinary Bladder NeoplasmsChemotherapy Adjuvant030220 oncology & carcinogenesisCohortBCG VaccineFemaleNeoplasm GradingbusinessAdjuvantUrologic oncology
researchProduct

Booster vaccination with hexavalent DTPa-HBV-IPV/Hib vaccine in the second year of life is as safe as concomitant DTPa-IPV/Hib + HBV administered sep…

2003

The safety and reactogenicity of a booster dose of GSK Biologicals' hexavalent DTPa-HBV-IPV/Hib vaccine (N=4725) was compared with the separate administration of GSK Biologicals' DTPa-IPV/Hib and HBV vaccines (N=4474) in two open, randomized multicenter studies (A and B). Solicited symptoms occurring within 4 days of vaccination were recorded on diary cards and serious adverse events (SAEs) were collected throughout the study period. In Study A (N=1149), incidences of solicited symptoms were similar in both groups; there were no SAEs either reported within 4 days of vaccination or considered to be causally related to vaccination. In study B (N=8050), where fever was the only solicited sympt…

Malemedicine.medical_specialtyFeverImmunization SecondaryBooster dosemedicine.disease_causecomplex mixturesInternal medicineConfidence IntervalsHumansMulticenter Studies as TopicMedicineHepatitis B VaccinesVaccines CombinedAdverse effectDiphtheria-Tetanus-Pertussis VaccineImmunization ScheduleHaemophilus VaccinesRandomized Controlled Trials as TopicHepatitis B virusBooster (rocketry)ReactogenicityGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryPublic Health Environmental and Occupational HealthInfantVaccinationPoliovirus Vaccine InactivatedInfectious DiseasesHib vaccineImmunizationImmunologyMolecular MedicineFemalebusinessVaccine
researchProduct

Smoking may increase the risk of influenza hospitalization and reduce influenza vaccine effectiveness in the elderly.

2017

Background Through its effects on the immune system, smoking may facilitate influenza virus infection, its severity and its most frequent complications. The objective was to investigate the smoking history as a risk factor for influenza hospitalization and influenza vaccine effectiveness in elderly smokers/ex-smokers and non-smokers. Methods We carried out a multicenter case-control study in the 2013-2014 and 2014-2015 influenza seasons. Cases aged ≥65 years and age-, sex-matched controls were selected from 20 Spanish hospitals. We collected epidemiological variables, comorbidities, vaccination history and the smoking history. The risk of hospitalization due to smoking (current smokers and …

Malemedicine.medical_specialtyInfluenza vaccineComorbidity03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicineEpidemiologyInfluenza HumanMedicineHumans030212 general & internal medicineRisk factorGeriatric AssessmentAgedAged 80 and overbusiness.industrySmokingPublic Health Environmental and Occupational HealthCase-control studyOdds ratiomedicine.diseaseComorbidityVaccinationHospitalizationIncreased riskTreatment Outcome030228 respiratory systemInfluenza VaccinesSpainCase-Control StudiesFemaleMedical emergencybusinessEuropean journal of public health
researchProduct

Influenza Vaccination After Myocardial Infarction:A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial

2021

Background: Observational and small, randomized studies suggest that influenza vaccine may reduce future cardiovascular events in patients with cardiovascular disease. Methods: We conducted an investigator-initiated, randomized, double-blind trial to compare inactivated influenza vaccine with saline placebo administered shortly after myocardial infarction (MI; 99.7% of patients) or high-risk stable coronary heart disease (0.3%). The primary end point was the composite of all-cause death, MI, or stent thrombosis at 12 months. A hierarchical testing strategy was used for the key secondary end points: all-cause death, cardiovascular death, MI, and stent thrombosis. Results: Because of the COV…

Malemedicine.medical_specialtyInfluenza vaccineMEDLINEMyocardial Infarction030204 cardiovascular system & hematologyPlacebolaw.invention03 medical and health sciences0302 clinical medicineRandomized controlled trialDouble-Blind MethodlawPhysiology (medical)Multicenter trialInternal medicineinfluenza vaccinesmedicineHumans030212 general & internal medicineMyocardial infarctionbusiness.industryMiddle Agedmedicine.disease3. Good healthVaccinationTreatment Outcomemyocardial infarctionInfluenza Vaccinesrandomized controlled trialObservational studyFemaleCardiology and Cardiovascular Medicinebusiness
researchProduct

Influenza vaccine concurrently administered with a combination measles, mumps, and rubella vaccine to young children.

2010

Children aged 11 to <24 months received 2 intranasal doses of live attenuated influenza vaccine (LAIV) or placebo, 35+/-7 days apart. Dose 1 was administered concomitantly with a combined measles, mumps, and rubella vaccine (Priorix). Seroresponses to measles and mumps were similar between groups. Compared with placebo, response rates to rubella in LAIV+Priorix recipients were statistically lower at a 15 IU/mL threshold (83.9% vs 78.0%) and the prespecified noninferiority criteria were not met. In a post hoc analysis using an alternate widely accepted threshold of 10 IU/mL, the noninferiority criteria were met (93.4% vs 89.8%). Concomitant administration with Priorix did not affect the over…

Malemedicine.medical_specialtyMeasles-Mumps-Rubella VaccineInfluenza vaccineAntibodies ViralVaccines AttenuatedRubellaMeaslesDrug IncompatibilityPlacebosRubella vaccineInternal medicineInfluenza HumanmedicineLive attenuated influenza vaccineHumansVaccines CombinedMumpsAdministration IntranasalRubellaGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryVaccinationPublic Health Environmental and Occupational HealthInfantmedicine.diseaseVaccinationInfectious DiseasesImmunizationInfluenza VaccinesImmunologyMolecular MedicineFemalebusinessMeasles-Mumps-Rubella Vaccinemedicine.drugMeaslesVaccine
researchProduct

[Clinical practice and adherence to the diagnosis and treatment of NMIBC guidelines: a report of a recognition based clinical cases study]

2014

For non-muscle invasive bladder cancer, a disease with a considerable epidemiological and socio-economic impact, the introduction of the Guidelines has always evoked as a tool for the resolution of long-standing disputes in terms of diagnosis and therapy. Check the degree of routine clinical practice adherence to the Recommendations is for this disease, more than for other uro-oncology pathology, an urgent need felt by the urological community. To assess the level of Guidelines adherence's, and study issues related to the paths of diagnosis and treatment of non-muscle invasive bladder cancer, and identifying the processes actually implemented in daily clinical practice, a series of case st…

Malemedicine.medical_specialtyPathologyMEDLINEAntineoplastic AgentsDiseaseEpidemiologymedicineHumansRoutine clinical practiceIntensive care medicineNeoplasm StagingBladder cancerbusiness.industryCarcinomaGeneral MedicineEvidence-based medicineMiddle Agedmedicine.diseaseClinical PracticeAdministration IntravesicalTreatment OutcomeUrinary Bladder NeoplasmsChemotherapy AdjuvantPractice Guidelines as TopicBCG VaccineGuideline AdherencebusinessStrengths and weaknesses
researchProduct

UNIVERSAL VARICELLA VACCINATION IN THE SICILIAN PAEDIATRIC POPULATION: RAPID UPTAKE OF THE VACCINATION PROGRAMME AND MORBIDITY TRENDS OVER FIVE YEARS

2009

Following the licensure of the Oka/Merck varicella vaccine in Italy in January 2003, the Sicilian health authorities launched a universal vaccination programme in all nine Local Health Units. A two-cohort vaccination strategy was adopted to minimise the shift of the mean age of varicella occurrence to older age groups, with the goal of vaccinating with one dose at least 80% of children in their second year of life and 50% of susceptible adolescents in their 12th year of life. Two studies were implemented in parallel to closely monitor vaccination coverage as well as varicella incidence. Overall, the programme achieved its target, with 87.5% vaccine coverage for the birth cohort 2005 and 90.…

Malemedicine.medical_specialtyPediatricsHerpesvirus 3 HumanVaricella vaccineSettore MED/17 - Malattie InfettiveAdolescentEpidemiologyVaricella vaccinationPediatricsChickenpox VaccineChickenpoxVirologymedicineHumansChildSicilybusiness.industryImmunization ProgramsIncidence (epidemiology)Public healthIncidencePublic Health Environmental and Occupational HealthInfantConfidence intervalVaccinationEl NiñoImmunizationChild PreschoolPopulation SurveillanceFemaleViral diseaseMorbiditybusiness
researchProduct

Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: a randomised non-inf…

2015

AbstractZostavax® is a live, attenuated varicella zoster virus (VZV) vaccine developed specifically for the prevention of HZ and PHN in individuals aged ≥50 years. During the clinical development of Zostavax, which was mainly in the US, the vaccine was administrated by the subcutaneous (SC) route. In Europe, many healthcare professionals prefer administering vaccines by the intramuscular (IM) route. This was an open-label, randomised trial conducted in 354 subjects aged ≥50 years. The primary objectives were to demonstrate that IM administration is both non-inferior to SC administration in terms of 4-week post-vaccination geometric mean titres (GMTs), and elicits an acceptable geometric mea…

Malemedicine.medical_specialtySub-cutaneous administration routeEnzyme-Linked Immunospot AssayHerpesvirus 3 HumanInjections SubcutaneousVaricella zoster virus vaccinePainmedicine.disease_causeAntibodies ViralVaccines AttenuatedHerpes ZosterInjections Intramuscularlaw.inventionShinglesInterferon-gammaRandomized controlled triallawImmunology and Microbiology(all)Internal medicinemedicineEdemaHerpes Zoster VaccineHumansAdverse effectAgedRandomised controlled trialAged 80 and overAttenuated vaccineIntention-to-treat analysisGeneral VeterinaryGeneral Immunology and Microbiologybusiness.industryELISPOTImmunogenicityVaccinationPublic Health Environmental and Occupational HealthVaricella zoster virusIntramuscular administration routeMiddle Agedmedicine.diseaseveterinary(all)Infectious DiseasesErythemaImmunologyMolecular MedicineFemalebusinessShinglesVaccine
researchProduct

Serologic control against hepatitis B virus among dental students of the University of Granada, Spain

2015

Background: To evaluate the immunological situation against hepatitis B virus (HBV) of a cohort of dentistry students, to analyze the behavior of the levels of hepatitis B surface antigen (anti-HBs) after the administration of one or three vaccine doses, and to determine the influence of age and sex on the immune response. Material and Methods: This retrospective cohort study included students attending the School of Dentistry of the institution where the study was performed from 2005 to 2012 who had completed the public health vaccination calendar for HBV at the age of 12-13. Data on age, sex, basal anti-HBs levels, post-vaccination anti-HBs results and final anti-HBs levels were collected…

Malemedicine.medical_specialtyUniversitieseducationStudents DentalOdontologíamedicine.disease_causeCohort StudiesYoung AdultInternal medicinemedicineHumansHepatitis B VaccinesYoung adultGeneral DentistryRetrospective StudiesHepatitis B virusOral Medicine and PathologyHepatitis B Surface Antigensbiologybusiness.industryResearchRetrospective cohort studyHepatitis B:CIENCIAS MÉDICAS [UNESCO]Hepatitis Bmedicine.diseaseCiencias de la saludVaccinationOtorhinolaryngologySpainUNESCO::CIENCIAS MÉDICASImmunologyCohortbiology.proteinFemaleSurgeryAntibodybusinessCohort studyMedicina Oral Patología Oral y Cirugia Bucal
researchProduct

Oral HPV Infection: Current Strategies for Prevention and Therapy

2012

Infection with High Risk (HR) Human Papillomaviruses (HPVs) is the main aetiological agent of Cervical Squamous Cell Carcinoma (CSCC) and also associated in a subgroup of other neoplasms, including Oropharyngeal Squamous cell Carcinoma (OPSCC). HPV infection, in genital as in oral mucosa, can also be subclinical or associated with benign proliferative lesions (common warts, condylomas, papillomas) caused mostly by infection with Low Risk (LR)-HPVs. In the last decades, extensive research has resulted in growing knowledge on HPV biology and specifically viral life cycle, biochemical properties of viral proteins and their interaction with the host proteins leading to potential new targets of …

Malemedicine.medical_specialtyUterine Cervical NeoplasmsSettore MED/28 - Malattie OdontostomatologicheDrug DiscoveryEpidemiologyAnimalsHumansMedicineSex organPapillomavirus VaccinesHealth EducationCommon wartsSubclinical infectionPharmacologyta313business.industryTransmission (medicine)Papillomavirus InfectionsHPV infectionvirus diseasesmedicine.diseasefemale genital diseases and pregnancy complicationsVaccinationOropharyngeal NeoplasmsCervical Squamous Cell CarcinomaHigh Risk (HR)HPV infectionDNA ViralImmunologyCarcinoma Squamous CellEtiologyRNA ViralFemaleMouth DiseasesbusinessCurrent Pharmaceutical Design
researchProduct